Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...

Background: Deficiency of DPD activity is associated with severe toxicity or even death after the first two cycles 5-fluorouracil (5-FU) based of chemotherapy. The objective of this study was to ...

In conclusion, we provide a rationale approach to improve the safety of fluoropirimidine-based therapy on an individual basis. Although our pharmacogenomic assay may be useful for all patients treated ...

Table 1. Genotyping analysis performed in our familial pharmacogenetic study. † MAF as identified in the CAUC2 population (rs55886062 and rs67376798), pilot_1_CEU_low_coverage_panel (rs75017182) or ...